Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Ricard Mesía"'
Publikováno v:
Pharmacology Research & Perspectives, Vol 12, Iss 1, Pp n/a-n/a (2024)
Abstract Off‐label use (OLU) is quite common in oncology due to the complexity of cancer and the time‐consuming regulatory process. However, outcomes of OLU in cancer treatment remain unclear. This study aimed to evaluate the overall survival (OS
Externí odkaz:
https://doaj.org/article/e641a54fb2d442639d55294939dbeaa6
Autor:
Sandra Fontanals, Anna Esteve, Andrea González, Cristina Ibáñez, Javier Martínez, Ricard Mesía, Ana Clopés
Publikováno v:
Cancer Medicine, Vol 12, Iss 16, Pp 17112-17125 (2023)
Abstract Purpose Medicines in special situations (MSS) refer to off‐label or to unlicensed drugs under investigation (compassionate use). Our objectives were to evaluate characteristics and to estimate overall survival (OS), event‐free survival (
Externí odkaz:
https://doaj.org/article/e109919815c54fed8ef7e66d141585d2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Juan A. Marín-Jiménez, Marc Oliva, Paloma Peinado Martín, Santiago Cabezas-Camarero, Maria Plana Serrahima, Gonzalo Vázquez Masedo, Alicia Lozano Borbalas, María N. Cabrera Martín, Anna Esteve, María C. Iglesias Moreno, Esther Vilajosana Altamis, Lorena Arribas Hortigüela, Miren Taberna Sanz, Pedro Pérez-Segura, Ricard Mesía
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
ObjectivesInduction chemotherapy (ICT) followed by definitive treatment is an accepted non-surgical approach for locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). However, ICT remains a challenge for cisplatin-unfit patients.
Externí odkaz:
https://doaj.org/article/9d6af13842bf47e6b926fa2e5a09c1cc
Publikováno v:
Current Opinion in Oncology. 35:145-150
Autor:
Sophie Wildsmith, Weimin Li, Song Wu, Ross Stewart, Nassim Morsli, Rajiv Raja, Qu Zhang, Jiabu Ye, Philip He, Jagdish Shetty, Alejandro Yovine, Nicholas Holoweckyj, Katia Real, Jill Walker, Magdalena Wrona, Melissa de los Reyes, Craig Barker, Jessica Whiteley, Robert Haddad, Lisa Licitra, Robert Ferris, Jérôme Fayette, Dan P. Zandberg, Lillian L. Siu, Ricard Mesía
Publikováno v:
Clinical Cancer Research. 29:2066-2074
Purpose: Biomarkers that predict response to immune checkpoint inhibitors (ICI) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) are needed. This retrospective study assessed tumor mutational burden (TMB) and outcomes in t
Autor:
Miren Taberna, Francisco Gil Moncayo, Enric Jané-Salas, Maite Antonio, Lorena Arribas, Esther Vilajosana, Elisabet Peralvez Torres, Ricard Mesía
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
The core function of a multidisciplinary team (MDT) is to bring together a group of healthcare professionals from different fields in order to determine patients' treatment plan. Most of head and neck cancer (HNC) units are currently led by MDTs that
Externí odkaz:
https://doaj.org/article/69a375cf4f394954b2d6310a6318f537
Autor:
Jesús García-Foncillas, Antonio Tejera-Vaquerizo, Onofre Sanmartín, Federico Rojo, Javier Mestre, Salvador Martín, Ignacio Azinovic, Ricard Mesía
Publikováno v:
Cancers, Vol 14, Iss 3, p 629 (2022)
Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer, the incidence of which has risen over the last years. Although cSCC rarely metastasizes, early detection and treatment of primary tumours are critical to limit pr
Externí odkaz:
https://doaj.org/article/e9db2bbe2afa487d9883a1adbbb1899e
Autor:
Eudald Felip, Lucía Gutiérrez-Chamorro, Maica Gómez, Edurne Garcia-Vidal, Margarita Romeo, Teresa Morán, Laura Layos, Laia Pérez-Roca, Eva Riveira-Muñoz, Bonaventura Clotet, Pedro Luis Fernandez, Ricard Mesía, Anna Martínez-Cardús, Ester Ballana, Mireia Margelí
Publikováno v:
Cancers, Vol 14, Iss 3, p 641 (2022)
SAMHD1 is a deoxynucleotide triphosphate (dNTP) triphosphohydrolase with important roles in the control of cell proliferation and apoptosis, either through the regulation of intracellular dNTPs levels or the modulation of the DNA damage response. How
Externí odkaz:
https://doaj.org/article/c6e5a79cb58843868b821bc667c24dd2